HDL-C in post-menopausal women: An important therapeutic target

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Women's Health

Background:

• Coronary heart disease (CHD) is a leading cause of mortality in Western women, particularly post-menopause.
• Menopause is associated with adverse metabolic changes, including dyslipidemia and metabolic syndrome features, increasing cardiovascular risk.
• Current lipid-modifying therapies primarily focus on low-density lipoprotein cholesterol (LDL-C).

Purpose of the Study:

• To evaluate the importance of lipid-modifying therapies beyond LDL-C reduction in post-menopausal women.
• To explore combination therapy strategies for managing dyslipidemia in high-risk women.
• To assess the role of fibrates and nicotinic acid in conjunction with statins.

Main Methods:

• Review of available data on lipid-modifying therapies in women.
• Analysis of treatment effects on lipid profiles, including triglycerides and high-density lipoprotein cholesterol (HDL-C).
• Consideration of combination therapy with statins, fibrates, and nicotinic acid.

Main Results:

• Dyslipidemia, characterized by elevated LDL-C, triglycerides, and lipoprotein(a), and decreased HDL-C, is a key risk factor.
• Fibrates are effective in lowering triglycerides; nicotinic acid excels at increasing HDL-C.
• Combination therapy may be more important for women than men, targeting multiple lipid parameters.

Conclusions:

• Combination lipid-modifying therapy is a logical strategy for managing cardiovascular risk in post-menopausal women.
• Further clinical trials specifically in women are needed to confirm optimal treatment approaches.
• Addressing dyslipidemia beyond LDL-C is essential for reducing CHD mortality in this demographic.